Back to Search Start Over

Polyphenolic Compounds as Pancreatic Lipase Inhibitors.

Authors :
Buchholz T
Melzig MF
Source :
Planta medica [Planta Med] 2015 Jul; Vol. 81 (10), pp. 771-83. Date of Electronic Publication: 2015 Jul 01.
Publication Year :
2015

Abstract

Obesity and its associated diseases such as diabetes mellitus and coronary heart diseases are a major challenge for our society. An important target for the treatment of obesity includes the development of inhibitors of nutrient digestion and absorption. Inhibition of pancreatic lipase and the associated reduction of lipid absorption is an attractive approach for the discovery of potent agents. Currently, the only clinically approved pharmacologic agent as pancreatic lipase inhibitor is Orlistat. However, its usage is compromised by unpleasant gastrointestinal adverse reactions (oily stools, oily spotting, flatulence). The use of botanical materials as a potential source of new drugs is of increasing importance and application. Natural products that are interesting for obesity treatment are generally considered to have less toxic and side effects than totally synthetic drugs. One of the most important sources of potential pancreatic lipase inhibitors represents the class of polyphenols. This article summarizes most studied subclasses of polyphenols including flavonoids, hydroxycinnamic acids, hydroxybenzoic acids and lignans with pancreatic lipase inhibitory effects. A structural comparison of potent inhibitors shows an increased inhibitory effect depending on number and position of phenolic hydroxyl groups, degree of polymerization and elimination of glycosylation during digestion.<br /> (Georg Thieme Verlag KG Stuttgart · New York.)

Details

Language :
English
ISSN :
1439-0221
Volume :
81
Issue :
10
Database :
MEDLINE
Journal :
Planta medica
Publication Type :
Academic Journal
Accession number :
26132857
Full Text :
https://doi.org/10.1055/s-0035-1546173